Benzinga | Jan 30, 2022 04:02PM EST

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st at 7:00 AM ET

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022.

The schedule for the press release and conference call/webcast is as follows:

MAESTRO-NAFLD-1 Press Release: January 31st, 2022 at 7:00 am ESTMAESTRO-NAFLD-1 Conference Call: January 31st, 2022 at 8:00 am ESTDomestic Dial-In Number: (833) 660-2754International Dial-In Number: (409) 350-3497Conference ID Number: 9170277To access the live webcast of the call please visit the Events and Presentations section of Madrigal's website or click here. An archived webcast will be available on the Madrigal website after the event.